Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential

Current Opinion in Pharmacology

Volumn 7, Issue 6, 2007, Pages 583-592

  Berna, Marc J ^a,c   Tapia, Jose A ^b,c   Sancho, Veronica ^c   Jensen, Robert T ^c  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF EXTREMADURA   (Spain)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [2,3 DIHYDRO 2 OXO 1 PIVALOYLMETHYL 5 (2 PYRIDYL) 1H 1,4 BENZODIAZEPIN 3 YL] 3 [3 (METHYLAMINO)PHENYL]UREA; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; ANALGESIC AGENT; ANTINEOPLASTIC AGENT; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; DEXLOXIGLUMIDE; GASTRIN; GASTRIN ANTAGONIST; GASTRIN RECEPTOR; GASTRIN RECEPTOR AGONIST; GLUTARAMIC ACID DERIVATIVE; HORMONE RECEPTOR STIMULATING AGENT; ITRIGLUMIDE; LORGLUMIDE; LOXIGLUMIDE; PENTAGASTRIN; PROGLUMIDE; PROTON PUMP INHIBITOR; SPIROGLUMIDE; TETRAGASTRIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE PANCREATITIS; ANALGESIA; CANCER INHIBITION; CHRONIC PANCREATITIS; CLINICAL TRIAL; CONSTIPATION; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPEPSIA; EATING DISORDER; GALLSTONE; GASTROINTESTINAL DISEASE; HORMONE ACTION; HORMONE DETERMINATION; HUMAN; HYPERGASTRINEMIA; IRRITABLE COLON; LONG TERM CARE; MONOTHERAPY; NONHUMAN; OBESITY; PANCREAS CANCER; PANCREATITIS; PANIC; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW;

EID: 36549009932     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.09.011     Document Type: Review

References (82)

1. Herranz R. Cholecystokinin antagonists: pharmacological and therapeutic potential. Med Res Rev 23 (2003) 559-605. A very comprehensive review that deals with all aspects of the chemistry of different classes of CCK1R and CCK2R antagonists.
2. de Tullio P., Delarge J., and Pirotte B. Therapeutic and chemical developments of cholecystokinin receptor ligands. Expert Opin Invest Drugs 9 (2000) 129-146
3. Berna M.J., and Jensen R.T. Role of CCK/gastrin receptors in gastrointestinal/metabolic diseases and results of human studies using gastrin/CCK receptor agonists/antagonists in these diseases. Curr Top Med Chem 7 (2007) 1211-1231. A comprehensive paper that reviews both studies of CCK ligands in gastrointestinal diseases as well as the data supporting potential uses in other disorders.
4. Jensen R.T. CCKB-gastrin receptor antagonists. Recent advances and potential uses in gastric secretory disorders. Yale J Biol Med 69 (1996) 245-259
5. Kalindjian S.B., and McDonald I.M. Strategies for the design of non-peptide CCK2 receptor agonist and antagonist ligand. Curr Top Med Chem 7 (2007) 1195-1204. An up-to-date report that reviews the development and characterization of the different classes of nonpeptide CCK2R agonists/antagonists.
6. Garcia-Lopez M.T., Gonzalez-Muniz R., Martin-Martinez M., and Herranz R. Strategies for design of non peptide CCK1R agonist/antagonist ligands. Curr Top Med Chem 7 (2007) 1180-1194. An up-to-date report that reviews the development and characterization of the different classes of nonpeptide CCK1R agonists/antagonists.
7. de Tullio P., Delarge J., and Pirotte B. Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists). Curr Med Chem 6 (1999) 433-455
8. Szewczyk J.R., and Laudeman C. CCK1R agonists: a promising target for the pharmacological treatment of obesity. Curr Top Med Chem 3 (2003) 837-854. A comprehensive review of the chemistry and pharmacology of recently developed nonpeptide CCK1R agonists.
9. Noble F. Pharmacology of CCKRs and SAR studies of peptidic analog ligands. Curr Top Med Chem 7 (2007) 1173-1179
10. Rehfeld J.F. Clinical endocrinology and metabolism. Cholecystokinin. Best Pract Res Clin Endocrinol Metab 18 (2004) 569-586
11. Dufresne M., Seva C., and Fourmy D. Cholecystokinin and gastrin receptors. Physiol Rev 86 (2006) 805-847. A up-to-date comprehensive review of the cell biology, pharmacology and physiology of both CCK and gastrin and their receptors.
12. McDonald I.M., Black J.W., Buck I.M., Dunstone D.J., Griffin E.P., Harper E.A., Hull R.A., Kalindjian S.B., Lilley E.J., Linney I.D., et al. Optimization of 1,3,4-benzotriazepine-based CCK(2) antagonists to obtain potent, orally active inhibitors of gastrin-mediated gastric acid secretion. J Med Chem 50 (2007) 3101-3112
13. Dockray G.J. Clinical endocrinology and metabolism. Gastrin. Best Pract Res Clin Endocrinol Metab 18 (2004) 555-568
14. Peter S.A., D'Amato M., and Beglinger C. CCK1 antagonists: are they ready for clinical use?. Dig Dis 24 (2006) 70-82. A concise review of the results of clinical studies of CCK1R antagonists as well as a review of the evidence suggesting other diseases they may be useful in.
15. Jensen R.T. Involvement of cholecystokinin/gastrin-related peptides and their receptors in clinical gastrointestinal disorders. Pharmacol Toxicol 91 (2002) 333-350. An extensive review of the investigated and possible gastrointestinal disorders that CCK or gastrin receptors may be involved in and in which either CCKR agonists or antagonists might be useful therapeutically.
16. Meyer B.M., Werth B.A., Beglinger C., Hildebrand P., Jansen J.B., Zach D., Rovati L.C., and Stalder G.A. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet 2 (1989) 12-15
17. Baber N.S., Dourish C.T., and Hill D.R. The role of CCK caerulein, and CCK antagonists in nociception. Pain 39 (1989) 307-328
18. Hebb A.L., Poulin J.F., Roach S.P., Zacharko R.M., and Drolet G. Cholecystokinin and endogenous opioid peptides: interactive influence on pain, cognition, and emotion. Prog Neuropsychopharmacol Biol Psychiatry 29 (2005) 1225-1238
19. McCleane G. Cholecystokinin antagonists a new way to improve the analgesia from old analgesics?. Curr Pharm Des 10 (2004) 303-314
20. Scarpignato C., Kisfalvi I., D'Amato M., and Varga G. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther 10 (1996) 411-419
21. Jensen R.T. Consequences of long-term proton pump blockade: highlighting insights from studies of patients with gastrinomas. Basic Clin Pharmacol Toxicol 98 (2006) 4-19
22. Lehmann F., Hildebrand P., and Beglinger C. New molecular targets for treatment of peptic ulcer disease. Drugs 63 (2003) 1785-1797
23. Miyasaka K., Ohta M., Kanai S., Yoshida Y., Sato N., Nagata A., Matsui T., Noda T., Jimi A., Takiguchi S., et al. Enhanced gastric emptying of a liquid gastric load in mice lacking cholecystokinin-B receptor: a study of CCK-A,B, and AB receptor gene knockout mice. J Gastroenterol 39 (2004) 319-323
24. Dauge V., and Lena I. CCK in anxiety and cognitive processes. Neurosci Biobehav Rev 22 (1998) 815-825
25. Chambers M.S., and Fletcher S.R. CCK-B antagonists in the control of anxiety and gastric acid secretion. Prog Med Chem 37 (2000) 45-81
26. Berna M.J., Hoffmann K.M., Serrano J., Gibril F., and Jensen R.T. Serum gastrin in Zollinger-Ellison syndrome. I. Prospective study of fasting serum gastrin in 309 patients from the National Institutes of Health and comparison with 2229 cases from the literature. Medicine (Baltimore) 85 (2006) 295-330
27. Ruszniewski P., Delle Fave G., Cadiot G., Komminoth P., Chung D., Kos-Kudla B., Kianmanesh R., Hochhauser D., Arnold R., Ahlman H., et al. Well-differentiated gastric tumors/carcinomas. Neuroendocrinology 84 (2006) 158-164
28. Cui G., and Waldum H.L. Physiological and clinical significance of enterochromaffin-like cell activation in the regulation of gastric acid secretion. World J Gastroenterol 13 (2007) 493-496
29. Qvigstad G., and Waldum H. Rebound hypersecretion after inhibition of gastric acid secretion. Basic Clin Pharmacol Toxicol 94 (2004) 202-208
30. Rehfeld J.F., Friis-Hansen L., Goetze J.P., and Hansen T.V. The biology of cholecystokinin and gastrin peptides. Curr Top Med Chem 7 (2007) 1154-1165. A up-to-date review of the biology and physiology of CCK and gastrin.
31. Dore M.P., and Graham D.Y. Pathogenesis of duodenal ulcer disease: the rest of the story. Baillieres Best Pract Res Clin Gastroenterol 14 (2000) 97-107
32. Baldwin G.S., and Shulkes A. CCK receptors and cancer. Curr Top Med Chem 7 (2007) 1232-1238. A concise report reviewing the evidence for the presence of CCKRs on human tumors and their effects on tumor growth.
33. Dockray G., Dimaline R., and Varro A. Gastrin: old hormone, new functions. Pflugers Arch 449 (2005) 344-355
34. Reubi J.C. Targeting CCK receptors in human cancers. Curr Top Med Chem 7 (2007) 1239-1242. A summary of the frequency of expression of CCKRs by different human tumors assessed by autoradiography and of their receptor densities.
35. Aly A., Shulkes A., and Baldwin G.S. Gastrins, cholecystokinins and gastrointestinal cancer. Biochim Biophys Acta 1704 (2004) 1-10
36. Reubi J.C., Macke H.R., and Krenning E.P. Candidates for peptide receptor radiotherapy today and in the future. J Nucl Med 46 Suppl. 1 (2005) 67S-75S
37. Laverman P., Behe M., Oyen W.J., Willems P.H., Corstens F.H., Behr T.M., and Boerman O.C. Two technetium-99 m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. Bioconjug Chem 15 (2004) 561-568
38. Breeman W.A., Kwekkeboom D.J., de Blois E., de Jong M., Visser T.J., and Krenning E.P. Radiolabelled regulatory peptides for imaging and therapy. Anticancer Agents Med Chem 7 (2007) 345-357
39. Gibril F., and Jensen R.T. Diagnostic uses of radiolabelled somatostatin-receptor analogues in gastroenteropancreatic endocrine tumors. Dig Liver Dis 36 (2004) S106-S120
40. Van Essen M., Krenning E.P., de Jong M., Valkema R., and Kwekkeboom D.J. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 46 (2007) 723-734
41. Crawley J.N., and Beinfeld M.C. Rapid development of tolerance to the behavioural actions of cholecystokinin. Nature 302 (1983) 703-706
42. Jensen R.T. Receptors on pancreatic acinar cells. In: Johnson L.R., Jacobson E.D., Christensen J., Alpers D.H., and Walsh J.H. (Eds). Physiology of the Gastrointestinal Tract. edn 3 (1994), Raven Press, New York 1377-1446
43. Witte D.G., Nadzan A.M., Martinez J., Rodriguez M., and Lin C.W. Characterization of the novel CCK analogs JMV-180, JMV-320, and JMV-332 in H345 cells. Peptides 13 (1992) 1227-1232
44. Spanarkel M.B., Martinez J., Briet C., Jensen R.T., and Gardner J.D. Cholecystokinin 27-32-amide. A member of a new class of cholecystokinin receptor antagonists. J Biol Chem 258 (1983) 6746-6749
45. Henke B.R., Aquino C.J., Birkemo L.S., Croom D.K., Dougherty Jr. R.W., Ervin G.N., Grizzle M.K., Hirst G.C., James M.K., Johnson M.F., et al. Optimization of 3-(1H-indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem 40 (1997) 2706-2725
46. Bignon E., Bachy A., Boigegrain R., Brodin R., Cottineau M., Gully D., Herbert J.M., Keane P., Labie C., Molimard J.C., et al. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I. In vitro studies. J Pharmacol Exp Ther 289 (1999) 742-751
47. Castillo E.J., gado-Aros S., Camilleri M., Burton D., Stephens D., O'Connor-Semmes R., Walker A., Shachoy-Clark A., and Zinsmeister A.R. Effect of oral CCK-1 agonist GI181771X on fasting and postprandial gastric functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 287 (2004) G363-G369
48. Katschinski M. Loxiglumide Rotta research. IDrugs 5 (2002) 469-474
49. Taniguchi H., Yomota E., Kume E., Shikano T., Endo T., and Nagasaki M. Effect of T-0632, a cholecystokininA receptor antagonist, on experimental acute pancreatitis. Jpn J Pharmacol 73 (1997) 105-112
50. Gould R.J., Fioravanti C., Cook P.G., and Solomon H.F. A model of gastric emptying in cats shows solid emptying is promoted by MK-329: a CCK antagonist. J Nucl Med 31 (1990) 1494-1499
51. Varga G. Dexloxiglumide Rotta Research Lab. Curr Opin Investig Drugs 3 (2002) 621-626
52. Trivedi B.K., and Hinton J.P. CI-1015. An orally active CCK-B receptor antagonist with an improved pharmacokinetic profile. Pharm Biotechnol 11 (1998) 481-505
53. Semple G., Ryder H., Rooker D.P., Batt A.R., Kendrick D.A., Szelke M., Ohta M., Satoh M., Nishida A., Akuzawa S., et al. (3R)-N-(1-(tert-Butylcarbonylmethyl)-2,3-dihydro-2-oxo-5-(2-pyridyl)-1H-1,4-benzodiazepin-3-yl)-N′-(3-(methylamino)phenyl)urea (YF476): a potent and orally active gastrin/CCK-B antagonist. J Med Chem 40 (1997) 331-341
54. Hughes J., Boden P., Costall B., Domeney A., Kelly E., Horwell D.C., Hunter J.C., Pinnock R.D., and Woodruff G.N. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci U S A 87 (1990) 6728-6732
55. Ziessman H.A. Cholecystokinin cholescintigraphy: clinical indications and proper methodology. Radiol Clin North Am 39 (2001) 997
56. Chen P.F., Nimeri A., Pham Q.H., Yuh J.N., Gusz J.R., and Chung R.S. The clinical diagnosis of chronic acalculous cholecystitis. Surgery 130 (2001) 578-581
57. Arora S., and Anubhuti. Role of neuropeptides in appetite regulation and obesity - a review. Neuropeptides 40 (2006) 375-401
58. Chaudhri O., Small C., and Bloom S. Gastrointestinal hormones regulating appetite. Philos Trans R Soc Lond B Biol Sci 361 (2006) 1187-1209
59. Hayes M.R., Chory F.M., Gallagher C.A., and Covasa M. Serotonin type-3 receptors mediate cholecystokinin-induced satiation through gastric distension. Am J Physiol Regul Integr Comp Physiol 291 (2006) R115-R123
60. Savastano D.M., and Covasa M. Intestinal nutrients elicit satiation through concomitant activation of CCK(1) and 5-HT(3) receptors. Physiol Behav 92 (2007) 434-442
61. Geracioti Jr. T.D., and Liddle R.A. Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 319 (1988) 683-688
62. Jordan J., Greenway F.L., Leiter L.A., Li Z., Jacobson P., Murphy K., Hill J., Kler L., and Aftring R.P. Stimulation of cholecystokinin-A receptors with GI181771X does not cause weight loss in overweight or obese patients. Clin Pharmacol Ther (2007). An important recent study providing convincing evidence that monotherapy with a CCK1R agonist is unlikely to be clinically useful in treatment of obesity.
63. Eser D., Schule C., Baghai T., Floesser A., Krebs-Brown A., Enunwa M., de la M.S., Engel R., Kucher K., and Rupprecht R. Evaluation of the CCK-4 model as a challenge paradigm in a population of healthy volunteers within a proof-of-concept study. Psychopharmacology (Berl) 192 (2007) 479-487
64. Bradwejn J., and Koszycki D. Cholecystokinin and panic disorder: past and future clinical research strategies. Scand J Clin Lab Invest Suppl 234 (2001) 19-27
65. Schunck T., Erb G., Mathis A., Gilles C., Namer I.J., Hode Y., Demaziere A., Luthringer R., and Macher J.P. Functional magnetic resonance imaging characterization of CCK-4-induced panic attack and subsequent anticipatory anxiety. Neuroimage 31 (2006) 1197-1208
66. Radu D., Ahlin A., Svanborg P., and Lindefors N. Pentagastrin test for anxiety - psychophysiology and personality. Psychopharmacology (Berl) 166 (2003) 139-145
67. Shiratori K., Takeuchi T., Satake K., and Matsuno S. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan. Pancreas 25 (2002) e1-e5
68. Mollereau C., Roumy M., and Zajac J.M. Opioid-modulating peptides: mechanisms of action. Curr Top Med Chem 5 (2005) 341-355. A recent review of the mechanisms of action of effects of CCK and other neuropeptides on opioid analgesia.
69. Hruby V.J., Porreca F., Yamamura H.I., Tollin G., Agnes R.S., Lee Y.S., Cai M., Alves I., Cowell S., Varga E., et al. New paradigms and tools in drug design for pain and addiction. AAPS J 8 (2006) E450-E460
70. Wiesenfeld-Hallin Z., Xu X.J., and Hokfelt T. The role of spinal cholecystokinin in chronic pain states. Pharmacol Toxicol 91 (2002) 398-403
71. Noble F., and Roques B.P. The role of CCK2 receptors in the homeostasis of the opioid system. Drugs Today (Barc) 39 (2003) 897-908
72. McCleane G.J. A randomised, double blind, placebo controlled crossover study of the cholecystokinin 2 antagonist L-365,260 as an adjunct to strong opioids in chronic human neuropathic pain. Neurosci Lett 338 (2003) 151-154
73. Sramek J.J., Kramer M.S., Reines S.A., and Cutler N.R. Pilot study of a CCKB antagonist in patients with panic disorder: preliminary findings. Anxiety 1 (1994) 141-143
74. Pande A.C., Greiner M., Adams J.B., Lydiard R.B., and Pierce M.W. Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 46 (1999) 860-862
75. Adams J.B., Pyke R.E., Costa J., Cutler N.R., Schweizer E., Wilcox C.S., Wisselink P.G., Greiner M., Pierce M.W., and Pande A.C. A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 15 (1995) 428-434
76. Mather S.J., McKenzie A.J., Sosabowski J.K., Morris T.M., Ellison D., and Watson S.A. Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy. J Nucl Med 48 (2007) 615-622
77. Chau I., Cunningham D., Russell C., Norman A.R., Kurzawinski T., Harper P., Harrison P., Middleton G., Daniels F., Hickish T., et al. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 94 (2006) 1107-1115. The first randomized studies involving a large group of patients with pancreatic cancer demonstrating the lack of effect of monotherapy with CCK2R antagonist.
78. Gotthardt M., Behe M.P., Grass J., Bauhofer A., Rinke A., Schipper M.L., Kalinowski M., Arnold R., Oyen W.J., and Behr T.M. Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocr Relat Cancer 13 (2006) 1203-1211
79. Gotthardt M., Behe M.P., Beuter D., Battmann A., Bauhofer A., Schurrat T., Schipper M., Pollum H., Oyen W.J., and Behr T.M. Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 33 (2006) 1273-1279. A recent study which demonstrates the potential clinical usefulness of gastrin receptor scintigraphy for identifying tumor locations which were not detected using the current widely used method of somatatatin receptor scintigraphy.
80. Buck I.M., Black J.W., Cooke T., Dunstone D.J., Gaffen J.D., Griffin E.P., Harper E.A., Hull R.A., Kalindjian S.B., Lilley E.J., et al. Optimization of the in vitro and in vivo properties of a novel series of 2,4,5-trisubstituted imidazoles as potent cholecystokinin-2 (CCK2) antagonists. J Med Chem 48 (2005) 6803-6812
81. Jensen R.T., Qian J.M., Lin J.T., Mantey S.A., Pisegna J.R., and Wank S.A. Distinguishing multiple CCK receptor subtypes. Studies with guinea pig chief cells and transfected human CCK receptors. Ann N Y Acad Sci 713 (1994) 88-106
82. Morton M.F., Barrett T., Yan W., Freedman J.M., Lagaud G., Prendergast C.E., Moreno V., Pyati J., Figueroa K., Li L., et al. JNJ-17156516 (3-[5-(3,4-dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-toly l-propionate) a novel, potent and selective CCK1 receptor antagonist. In vitro and in vivo pharmacological comparison with dexloxiglumide. J Pharmacol Exp Ther (2007)